Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 4/2008

01-04-2008 | Melanomas

TNF-Based Isolated Limb Perfusion Followed by Consolidation Biotherapy with Systemic Low-dose Interferon Alpha 2b in Patients with In-transit Melanoma Metastases: A Pilot Trial

Authors: Carlo Riccardo Rossi, MD, Francesco Russano, MD, Simone Mocellin, MD, PhD, Vanna Chiarion-Sileni, MD, Mirto Foletto, MD, Pierluigi Pilati, MD, Luca G. Campana, MD, Antonio Zanon, MD, Gian Franco Picchi, MD, Mario Lise, MD, Donato Nitti, MD

Published in: Annals of Surgical Oncology | Issue 4/2008

Login to get access

Abstract

Background

Tumor necrosis factor (TNF)-based isolated limb perfusion (ILP) yields high tumor response rates in patients with in-transit melanoma metastases. However, most patients will ultimately experience disease recurrence. The aim of this pilot study was to test the hypothesis that systemic low-dose interferon α-2b (LDI) might consolidate the therapeutic effect of ILP.

Methods

A total of 12 patients with in-transit melanoma metastases not amenable to surgical excision were given LDI subcutaneously (3 million IU/day, 7 days/week for 12 months) after TNF-based ILP (TNF 1 mg + melphalan (L-PAM) 10 mg/L) (group A). The clinical outcome of these patients was historically compared with that of 19 patients with similar anthropometric and disease characteristics who underwent TNF-based ILP alone (group B).

Results

In group A, LDI was well tolerated, only grade 2 systemic toxicity being recorded in 50% of patients. The progression-free survival analysis showed a statistically significant advantage for group A patients as compared with group B (median time to progression: 26 and 17 months, respectively; log-rank test P-value: 0.037). This survival benefit was confirmed at multivariate analysis, where treatment was the only prognostic factor retained by the prediction model. The analysis of the risk of disease progression over time suggested that this survival benefit appears to vanish after LDI discontinuation, which further strengthens the hypothesis that LDI might consolidate the therapeutic effect of TNF-based ILP.

Conclusions

These preliminary findings support the conduction of larger trials to formally assess the ability of LDI to improve the clinical outcome of melanoma patients with in-transit metastases undergoing TNF-based ILP.
Literature
1.
Balch CM, Houghton A, Sober AJ, et al. Cutaneous melanoma, 4th ed. Quality Medical Publishing Corporation, St. Louis; 2003
2.
Grunhagen DJ, de Wilt JH, van Geel AN, et al. Isolated limb perfusion for melanoma patients–a review of its indications and the role of tumour necrosis factor-alpha. Eur J Surg Oncol. 2006;32:371–80.PubMedCrossRef
3.
Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol. 2003;4:429–37.PubMedCrossRef
4.
Noorda EM, Vrouenraets BC, Nieweg OE, et al. Isolated limb perfusion in regional melanoma. Surg Oncol Clin North Am. 2006;15:373–84.CrossRef
5.
Rossi CR, Foletto M, Pilati P, et al. Isolated limb perfusion in locally advanced cutaneous melanoma. Semin Oncol. 2002;29:400–9.PubMedCrossRef
6.
Lejeune FJ, Lienard D, Matter M, et al. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun. 2006;6:6.PubMed
7.
Mocellin S, Rossi CR, Pilati P, et al. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev. 2005;16:35–53.PubMedCrossRef
8.
Ruegg C, Yilmaz A, Bieler G, et al. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med. 1998;4:408–14.PubMedCrossRef
9.
Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157–64.PubMedCrossRef
10.
Parmar S, Platanias LC. Interferons: mechanisms of action and clinical applications. Curr Opin Oncol. 2003;15:431–9.PubMedCrossRef
11.
Indraccolo S, Tisato V, Tosello V, et al. Interferon-alpha gene therapy by lentiviral vectors contrasts ovarian cancer growth through angiogenesis inhibition. Hum Gene Ther. 2005;16:957–70.PubMedCrossRef
12.
Slaton JW, Perrotte P, Inoue K, et al. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res. 1999;5:2726–34.PubMed
13.
Ozawa S, Shinohara H, Kanayama HO, et al. Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-alpha. Neoplasia. 2001;3:154–64.PubMedCrossRef
14.
von Marschall Z, Scholz A, Cramer T, et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst. 2003;95:437–48.CrossRef
15.
Rossi CR, Foletto M, Mocellin S, et al. Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and melphalan for bulky in-transit melanoma metastases. Ann Surg Oncol. 2004;11:173–7.PubMedCrossRef
16.
Wieberdink J, Benckhuysen C, Braat RP, et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982;18:905–10.PubMedCrossRef
17.
Casara D, Rubello D, Pilati P, et al. Optimized procedure of real-time systemic leakage monitoring during isolated limb perfusion using a hand held gamma probe and 99mTc-HSA. Nucl Med Commun. 2004;25:61–6.PubMedCrossRef
18.
Cornett WR, McCall LM, Petersen RP, et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol. 2006;24:4196–201.PubMedCrossRef
19.
Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635–48.PubMed
Metadata
Title
TNF-Based Isolated Limb Perfusion Followed by Consolidation Biotherapy with Systemic Low-dose Interferon Alpha 2b in Patients with In-transit Melanoma Metastases: A Pilot Trial
Authors
Carlo Riccardo Rossi, MD
Francesco Russano, MD
Simone Mocellin, MD, PhD
Vanna Chiarion-Sileni, MD
Mirto Foletto, MD
Pierluigi Pilati, MD
Luca G. Campana, MD
Antonio Zanon, MD
Gian Franco Picchi, MD
Mario Lise, MD
Donato Nitti, MD
Publication date
01-04-2008
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 4/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9791-z

Other articles of this Issue 4/2008

Annals of Surgical Oncology 4/2008 Go to the issue

Gastrointestinal Oncology

Selection for Resection of Hepatocellular Carcinoma and Surgical Strategy: Indications for Resection, Evaluation of Liver Function, Portal Vein Embolization, and Resection

Gastrointestinal Oncology

More Controversy than Ever – Challenges and Promises Towards Personalized Treatment of Gastric Cancer

Gastrointestinal Oncology

Color Doppler Imaging Predicts Portal Invasion by Pancreatic Adenocarcinoma

Medical Oncology

The Growing Evidence of the Role of T-Cells in the Treatment of Solid Tumors

Breast Oncology

The Genomic Heritage of Lymph Node Metastases: Implications for Clinical Management of Patients with Breast Cancer

Gastrointestinal Oncology

Isolated Chemotherapeutic Perfusion of Pelvis as Neoadjuvant or Palliative Therapy for Advanced Cancer of the Rectum